3 Stocks I'm Not Selling No Matter What the Market Does for the Next 20 Years

The article is a bullish long-term endorsement of Berkshire Hathaway, Intuitive Surgical, and Nvidia, highlighting durable business models, strong management, and attractive or reasonable valuations. It cites Intuitive Surgical's Q1 procedures up 17% and revenue up 23%, and Nvidia's Q1 revenue of $81.6B, up 85% year over year, with data center revenue up 92% to $75.2B. The piece is opinion-driven rather than event-driven, so the near-term market impact should be limited.

Analysis

The common thread here is not “quality” in the generic sense; it is monetization durability. BRK.B is the clearest defensive compounder because its float and operating mix should outperform in a drawdown, while ISRG and NVDA are higher-beta cash-flow machines whose moats are widening through installed-base economics and ecosystem lock-in. The second-order setup is that capital is likely to keep flowing toward businesses where recurring revenue and pricing power can survive a recessionary scare, which argues for owning the leaders and fading economically exposed imitators rather than betting on broad thematic baskets.

The market is still underestimating how much of NVDA’s runway depends on capex concentration rather than end-demand. If hyperscaler spending pauses for even one or two quarters, the stock can derate faster than fundamentals because expectations are now embedded in the entire AI supply chain; that creates a sharp but potentially temporary air pocket. ISRG has a different risk: adoption is structurally strong, but hospitals can stretch replacement cycles if financing costs stay elevated, so the near-term multiple support is more sensitive to rates than the headline procedure growth suggests.

Contrarianly, the “reasonable valuation” framing may be too complacent for NVDA and ISRG if their historical multiples were set during periods of lower rates and less crowded ownership. The better asymmetry is probably in BRK.B as a cash-rich volatility absorber and in relative-value structures that express quality-vs-cyclicals rather than outright index beta. If a broad market correction hits in the next 1-3 quarters, these names should still outperform, but NVDA is the one most likely to experience the largest multiple compression before fundamentals reassert.

Key Decisions for Investors

• Long BRK.B vs. SPY into any 3%-5% market pullback over the next 1-2 months; target relative outperformance of 200-300 bps with downside protection from lower beta.
• Maintain core long NVDA, but hedge with a 3-6 month call spread overwrite or a small short against a high-multiple AI supplier basket; risk is a capex pause causing a sharp 15%-20% de-rating even if growth stays strong.
• Add ISRG on weakness after any post-earnings selloff; structure as a 6-12 month entry because procedure growth is the driver, but rate sensitivity can keep the stock range-bound near term.
• Pair long BRK.B / short a basket of leveraged cyclical financials and industrials for a recession-scare hedge; this captures the likely flight to quality without relying on market direction.